First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955

COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER

Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer: A Randomized Trial

Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377

Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1

Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G. V., Rosell, R., Miller, V. A., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,712

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701

American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003

Pfister, D. G., Johnson, D. H., Azzoli, C. G., Sause, W. T., Smith, T. J., Baker, S., Olak, J., Stover, D. E., Strawn, J. R., Turrisi, A. T., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.053 · Cited by 1,411

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

Masuda, T., Imai, H., Kuwako, T., Miura, Y., Yoshino, R., Kaira, K., Shimizu, K., Sunaga, N., Tomizawa, Y., Ishihara, S., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1297-8 · Cited by 16

Tyrosine Kinase Inhibitors for the Elderly

Hohenforst‐Schmidt, W., Zarogoulidis, P., Steinheimer, M., Benhassen, N., Tsiouda, T., Baka, S., Yarmus, L. B., Stratakos, G. K., Organtzis, J., Pataka, A., et al. (2016) · Journal of Cancer · doi:10.7150/jca.14819 · Cited by 15

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

Liao, B.-C., Lin, C., & Yang, J. C. (2013) · Drugs · doi:10.1007/s40265-013-0020-8 · Cited by 16

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer

Yin, Y., Geng, Y., Shao, Y., Hu, X., Li, W., Shu, Y., & Wang, Z.-X. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-126 · Cited by 15

Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC

Jiang, Q., Zhang, N., Ma, D., Tan, B., Hu, X., & Fang, X. (2019) · Medicine · doi:10.1097/md.0000000000016065 · Cited by 15

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401

Iwama, E., Goto, Y., Murakami, H., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0728 · Cited by 15

Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases

Chen, Y.-L., Lu, C., Yang, S.-C., Su, W., Lin, Y.-L., Chen, W.-L., Huang, W., Su, W., Chow, N.-H., & Ho, C. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.05.007 · Cited by 15

Lazarus response to treatment of patients with lung cancer and oncogenic mutations in the intensive care unit

Chien, C., & Chen, H.-J. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.110 · Cited by 15

Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter prospective SMILE study

Wei, Y., Huang, W.-T., Liu, T.-C., Shieh, J.-M., Chian, C., Wu, M., Chang, C.-C., Lin, C., Ko, J., Lin, C.-M., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30507 · Cited by 15

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation

Tanaka, H., Taima, K., Makiguchi, T., Nakagawa, J., Niioka, T., & Tasaka, S. (2021) · 癌症：英文版 · doi:10.1002/cac2.12124 · Cited by 15

Relationship between EGFR mutations and clinicopathological features of lung adenocarcinomas diagnosed via small biopsies.

Kim, H. J., Choi, E. Y., Jin, H. J., & Shin, K. (2014) · PubMed · Cited by 14

A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond

Reck, M. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.63 · Cited by 14

NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer

Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14

Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non–small-Cell Lung Cancer Involvement in the ICU

Tandjaoui-Lambiotte, Y., Akrour, Y., Gibelin, A., Gonzalez, F., Stoclin, A., Moreau, A., Jaubert, P., Oppenheimer, A., Duchemann, B., & Gaudry, S. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.079 · Cited by 14

Safety and utility of Endoscopic Ultrasound with Bronchoscope-guided Fine Needle Aspiration (EUS-B-FNA) in suspected lung cancer patients with poor respiratory or general conditions: a prospective three-center observational study

Nakashima, K., Umeda, Y., Demura, Y., Takeda, T., Tada, T., Sato, M., Jikuya, N., Kurokawa, K., Sonoda, T., Yamaguchi, M., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02508-2 · Cited by 14

Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer

Eccles, B., Geldart, T., Laurence, V., Bradley, K., & Lwin, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011409096 · Cited by 14

Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Sakai, H., Hayashi, H., Iwasa, T., Hasegawa, Y., Takeda, M., & Nakagawa, K. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000104 · Cited by 14

Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)

Okuma, Y., Morikawa, K., Tanaka, H., Yokoyama, T., Itani, H., Horiuchi, K., Nakagawa, H., Takahashi, N., Bessho, A., Soejima, K., et al. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12923 · Cited by 14

Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV

Gounant, V., Lavolé, A., & Quoix, É. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.025 · Cited by 14

PNA-mediated Real-Time PCR Clamping for Detection of EGFR Mutations

Choi, J., Cho, M.-H., Oh, M., Kim, H.-S., Kil, M.-S., & Park, H.-K. (2010) · Bulletin of the Korean Chemical Society · doi:10.5012/bkcs.2010.31.12.3525 · Cited by 14

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations

Yoshida, K., Yatabe, Y., Jangchul, P., Ogawa, S., Park, J. Y., Shimizu, J., Horio, Y., Matsuo, K., Mitsudomi, T., & Hida, T. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0685-2 · Cited by 13

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients

Pircher, A., Ploner, F., Popper, H., & Hilbe, W. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.01.017 · Cited by 13

Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy

Sekine, A., & Satoh, H. (2017) · Medical Oncology · doi:10.1007/s12032-017-0978-2 · Cited by 13

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

Hulo, P., Coupez, D., Denis, M. G., & Bennouna, J. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1757439 · Cited by 14

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report

Ninomaru, T., Okada, H., Fujishima, M., Irie, K., Fukushima, S., & Hata, A. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100145 · Cited by 13

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Miyawaki, T., Kenmotsu, H., Kodama, H., Nishioka, N., Miyawaki, E., Mamesaya, N., Kobayashi, H., Omori, S., Ko, R., Wakuda, K., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08983-2 · Cited by 13

Gefitinib for non-small-cell lung cancer treatment

D’Incecco, A., & Cappuzzo, F. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.617738 · Cited by 13

Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

Kurishima, K., Satoh, H., Kaburagi, T., Nishimura, Y., Shinohara, Y., Inagaki, M., Endo, T., Saito, T., Hayashihara, K., Hizawa, N., et al. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.154 · Cited by 13

Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77

Riggs, H., Jalal, S. I., Baghdadi, T. A., Bhatia, S., McClean, J., Johnson, C. S., Yu, M., Taber, D. A., Harb, W. A., & Hanna, N. H. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.004 · Cited by 13

Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity

Ueda, H., Hayashi, H., Kudo, K., Takeda, M., & Nakagawa, K. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0384-1 · Cited by 13

Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma—A Systematic Review

Brouns, A., Dursun, S., Bootsma, G. P., Dingemans, A. C., & Hendriks, L. E. L. (2021) · Cancers · doi:10.3390/cancers13133144 · Cited by 13

Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists

Mazzone, P. J., & Mekhail, T. M. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2011.10.016 · Cited by 15

Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment

Hirasawa, Y., Kubota, Y., Mura, E., Suzuki, R., Tsurui, T., Iriguchi, N., Ishiguro, T., Ohkuma, R., Shimokawa, M., Ariizumi, H., et al. (2024) · Anticancer Research · doi:10.21873/anticanres.17160 · Cited by 12

Epidermal growth factor receptor-tyrosine kinase inhibitors for non-small-cell lung cancer patients aged 80 years or older: A retrospective analysis

Nakao, M., Muramatsu, H., Sone, K., AOKI, S., AKIKO, H., Kagawa, Y., Sato, H., & Kunieda, T. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.453 · Cited by 12

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

Costanzo, R., Montanino, A., Maïo, M. D., Piccirillo, M. C., Sandomenico, C., Giordano, P., Daniele, G., Franco, R., Perrone, F., Rocco, G., et al. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.845092 · Cited by 12

Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old

Forest, F., Patoir, A., Col, P. D., Cruz, V. D., Camy, F., Stachowicz, M., Bayle-Bleuez, S., Fournel, P., Karpathiou, G., & Péoc’h, M. (2018) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000678 · Cited by 12

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data

Noda‐Narita, S., Kawachi, A., Okuyama, A., Sadachi, R., Hirakawa, A., Goto, Y., Fujiwara, Y., Higashi, T., & Yonemori, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257489 · Cited by 12

Pharmacokinetics of Gefitinib in a Patient with Non-Small Cell Lung Cancer Undergoing Continuous Ambulatory Peritoneal Dialysis

Yamaguchi, T., Isogai, S., Okamura, T., Uozu, S., Mieno, Y., Hoshino, T., Gotô, Y., Hayashi, M., Nakanishi, T., & Imaizumi, K. (2015) · Case Reports in Oncology · doi:10.1159/000375485 · Cited by 12

Phase II Study of Cetuximab, Docetaxel, and Gemcitabine in Patients With Previously Untreated Advanced Non–Small-Cell Lung Cancer

Spigel, D. R., Greco, F. A., Thompson, D. S., Webb, C. D., Rubinsak, J. R., Inhorn, R. C., Reeves, J. E., Vázquez, E. R., Lane, C. M., Burris, H. A., et al. (2010) · Clinical Lung Cancer · doi:10.3816/clc.2010.n.026 · Cited by 12

Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification.

Revannasiddaiah, S., Thakur, P., Bhardwaj, B., Susheela, S. P., & Madabhavi, I. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2014.05.19 · Cited by 11

Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study

Katayama, T., Matsuo, K., Kosaka, T., Sueda, T., Yatabe, Y., & Mitsudomi, T. (2010) · Surgical Oncology · doi:10.1016/j.suronc.2010.07.002 · Cited by 11

EGFR mutations in malignant pleural effusions from lung cancer

Shamblin, C. J., Tanner, N. T., Sanchez, R., Woolworth, J. A., & Silvestri, G. A. (2013) · Current Respiratory Care Reports · doi:10.1007/s13665-013-0041-5 · Cited by 11

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer

Zaarour, M., Weerasinghe, C. K., Nazha, B., Hassan, S., & Atallah, J. P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1092385 · Cited by 11

Performance status as prognostic factor in phase III trials of first‐line chemotherapy of unresectable or metastatic pancreatic cancer: A trial‐level meta‐analysis

Colloca, G. A. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13598 · Cited by 11

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis ( TOPGAN2020 ‐02)

Tanaka, H., Sakamoto, H., Akita, T., Ohyanagi, F., Kawashima, Y., Tambo, Y., Tanimoto, A., Horiike, A., Miyauchi, E., Tsuchiya‐Kawano, Y., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14415 · Cited by 12

The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation

Hsia, T., Tu, C., & Chen, H.-J. (2014) · BMC Anesthesiology · doi:10.1186/1471-2253-14-55 · Cited by 11

Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report

Uemura, T., Oguri, T., Okayama, M., Furuta, H., Kanemitsu, Y., Takakuwa, O., Ohkubo, H., Takemura, M., Maeno, K., Ito, Y., et al. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1181 · Cited by 11

ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib

Sakamoto, S., Sato, K., Takita, Y., Izumiya, Y., Kumagai, N., Sudo, K., Hasegawa, Y., Yokota, H., Akamine, Y., Okuda, Y., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00946-x · Cited by 11

Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study

Nasu, S., Suzuki, H., Shiroyama, T., Tanaka, A., Samejima, Y., Kanai, T., Noda, Y., Morishita, N., Okamoto, N., & Hirashima, T. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00963-w · Cited by 11

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial

Harada, D., Isozaki, H., Kozuki, T., Yokoyama, T., Yoshioka, H., Bessho, A., Hosokawa, S., Takata, I., Takigawa, N., Hotta, K., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13825 · Cited by 11

Tyrosine Kinase Inhibitors Improved Survival of Critically Ill EGFR-Mutant Lung Cancer Patients Undergoing Mechanical Ventilation

Lee, I.-H., Yang, C., Shih, J., & Yu, C. (2021) · Biomedicines · doi:10.3390/biomedicines9101416 · Cited by 11

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer

Kaburagi, T., Satoh, H., Hayashihara, K., Endo, T., Hizawa, N., Kurishima, K., Nishimura, Y., Hashimoto, T., Nakamura, H., Kishi, K., et al. (2012) · Oncology Letters · doi:10.3892/ol.2012.1048 · Cited by 11

A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases

Chen, Y., Fang, Y.-T., Lai, C., Rau, K., Huang, C.-H., Chang, H., Chao, T.-Y., Tseng, C., Fang, W., Wang, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167923 · Cited by 11

Treatment of EGFR mutation-positive non–small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report

Nonagase, Y., Takeda, M., Tanaka, K., Hayashi, H., Iwasa, T., & Nakagawa, K. (2018) · Oncotarget · doi:10.18632/oncotarget.25687 · Cited by 11

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

Togashi, Y., Hayashi, H., Nakagawa, K., & Nishio, K. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s50358 · Cited by 11

The efficacy and safety of first-line therapy for the epidermal growth factor receptor mutant non-small cell lung cancer in older versus younger patients: A pooled analysis of two randomized controlled trials

Noronha, V., Kapoor, A., Patil, V. M., Joshi, A., Menon, N. N., Chougule, A., Chandrani, P., Trivedi, V., Behel, V., Kumar, R., et al. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_35_20 · Cited by 10

Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience

Lamy, T., Cabarrou, B., Planchard, D., Quantin, X., Schneider, S., Bringuier, M., Besse, B., Girard, N., CHOUAID, C., Filleron, T., et al. (2021) · Cancers · doi:10.3390/cancers14010092 · Cited by 10

Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly

Minuti, G., D’Incecco, A., & Cappuzzo, F. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0305-6 · Cited by 10

Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma

Arfaoui, A. T., Mahmoud, L. K. B., Znaidi, N. S., Gritli, S., Bouacha, H., Zermani, R., & Rammeh, S. (2013) · Journal of Immunoassay and Immunochemistry · doi:10.1080/15321819.2013.848813 · Cited by 10

Are TKIs favourable for the elderly with non-small-cell lung cancer?

Rossi, S., D’Argento, E., Schinzari, G., Dadduzio, V., Noia, V. D., Cassano, A., & Barone, C. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9389 · Cited by 10

Obtaining tissue diagnosis in lung cancer patients with poor performance status and its influence on treatment and survival

Maclay, J. D., Farley, J., McCowan, C., Tweed, C., & Milroy, R. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.01.002 · Cited by 10

Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review

Nie, N., Liu, Z.-L., Feng, M., Liu, L., Luo, N., Li, L., & He, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2279 · Cited by 10

Flexible bronchoscopy for lung cancer diagnosis in patients aged ≥85 years

Mineshita, M., Morikawa, K., Furuya, N., Kida, H., Nishine, H., Handa, H., & Inoue, T. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14313 · Cited by 10

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

Bronte, G., Cosi, D. M., Magri, C., Frassoldati, A., Crinò, L., & Calabrò, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612622 · Cited by 10

Epidermal growth factor receptor inhibitors in non-small cell lung cancer: current status and future perspectives

Zukin, M. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1590/s0104-42302012000200025 · Cited by 10

Chemotherapy is Beneficial for Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Analysis of Patients Aged 70-74, 75-79, and 80 or Older in Japan

Kawaguchi, T., Tamiya, A., Tamura, A., Arao, M., Saito, R., Matsumura, A., Ou, S. I., & Tamura, T. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.03.010 · Cited by 10

KRAS Wild-Type Lung Cancer: A Moving Target in an Era of Genotype Migration

Oxnard, G. R., & Janne, P. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2740 · Cited by 10

Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Patients With Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2

Saito, H., Nakagawa, K., Takeda, K., Iwamoto, Y., Ando, M., Maeda, M., Katakami, N., Nakano, T., Kurata, T., & Fukuoka, M. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318201a0f3 · Cited by 9

Addition of vandetanib to chemotherapy in advanced solid cancers

Wu, X., Jin, Y., Cui, I. H., Xu, Z., Zhang, Y., Zhang, X., Tang, C., Gong, Y., & Chen, J. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835514f4 · Cited by 9

Malignant neoplasm of the bronchi and lung: Russian clinical guidelines

Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Breder, V. V., Маркович, Б. Ю., Vladimirova, L. Y., Волков, Н. М., Ергнян, С. М., Жабина, А. С., Kononets, P. V., et al. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.3.201848 · Cited by 9

Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study

Morimoto, K., Yamada, T., Takeda, T., Shiotsu, S., Date, K., Tamiya, N., Gotô, Y., Kanda, H., Chihara, Y., Kunimatsu, Y., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00991-5 · Cited by 10

Gefitinib for a Poor Performance Status Patient with Squamous Cell Carcinoma of the Lung Harboring EGFR Mutation

Tanaka, K., Hata, A., Kida, Y., Kaji, R., Fujita, S., Katakami, N., & Imai, Y. (2012) · Internal Medicine · doi:10.2169/internalmedicine.51.6386 · Cited by 9

A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer

Sakamoto, T., Kodani, M., Takata, M., Chikumi, H., Nakamoto, M., Nishii‐Ito, S., Ueda, Y., Izumi, H., Makino, H., Touge, H., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2875 · Cited by 9

Practice pearls in the management of lung cancer in the elderly

Kanesvaran, R., Chowdhury, A. R., & Krishna, L. K. R. (2016) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2016.05.004 · Cited by 9

Dramatic response of acute disseminated intravascular coagulation to erlotinib in a patient with lung adenocarcinoma with activating EGFR mutation

Kim, J. S., Ryu, J., Jeon, S. H., Kim, H. J., Nam, H.-S., Cho, J. H., Kwak, S. M., & Lee, H. L. (2017) · Journal of International Medical Research · doi:10.1177/0300060517720099 · Cited by 9

Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?

Booton, R., Blackhall, F. H., & Kerr, K. M. (2011) · Thorax · doi:10.1136/thx.2010.138370 · Cited by 9

Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status

Gijtenbeek, R. G. P., de Jong, K., Venmans, B. J. W., van Vollenhoven, F. H. M., Brinke, A. T., van der Wekken, A. J., & van Geffen, W. H. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013382.pub2 · Cited by 8

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic

Lakkunarajah, S., Truong, P. T., Bone, J. N., Hughesman, C. B., Yip, S. S. F., Alex, D., Hart, J., Pollock, P., Egli, S., Clarkson, M., et al. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-81 · Cited by 9

Positron Emission Tomography and Circulating Tumor Cells to Monitor a Dramatic Response to Gefitinib

Morabito, A., Sandomenico, C., Costanzo, R., Montanino, A., Caracò, C., Lutio, E. D., Bevilacqua, S., Pasquale, R., Caronna, A., Botti, G., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182653da2 · Cited by 8

The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer.

Voon, P. J., Cho, B. C., Yeo, W.-L., & Soo, R. A. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.6 · Cited by 8

The role of Gefitinib in patients with non-small-cell lung cancer in India

Mehta, A. A., Jose, W. M., Pavithran, K., & Triavadi, G. (2013) · Indian Journal of Palliative Care · doi:10.4103/0973-1075.110237 · Cited by 8

Osimertinib administration via nasogastric tube in an EGFR‐T790M ‐positive patient with leptomeningeal metastases

Takeda, T., Itano, H., Takeuchi, M., Nishimi, Y., Saitoh, M., & Takeda, S. (2017) · Respirology Case Reports · doi:10.1002/rcr2.241 · Cited by 8

Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity

Yamanaka, Y., Sekine, A., Kato, T., Yamakawa, H., Ikeda, S., Baba, T., Iwasawa, T., Okudela, K., & Ogura, T. (2017) · Internal Medicine · doi:10.2169/internalmedicine.8638-16 · Cited by 8

Safety and efficacy of diagnostic flexible bronchoscopy in very old patients with lung cancer

Okachi, S., Imaizumi, K., Imai, N., Shimizu, T., Hase, T., Morise, M., Hashimoto, N., Sato, M., & Hasegawa, Y. (2018) · European Geriatric Medicine · doi:10.1007/s41999-018-0033-7 · Cited by 8

Early Fatal Hemoptysis After First-Dose, in a Central Lung Cancer: Did Tumor Shrinkage Matter?

Facchinetti, F., Majori, M., Sabato, M., Gnetti, L., & Tiseo, M. (2019) · Immunotherapy · doi:10.2217/imt-2018-0136 · Cited by 8

Clinical outcomes of pembrolizumab therapy in advanced‐ NSCLC patients with poor performance status (≥3) and high PD‐L1 expression ( TPS ≥50%): A case series

Higashiyama, R. I., Yoshida, T., Jo, H., Shirasawa, M., Motoi, N., & Ohe, Y. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13713 · Cited by 8

First-line Osimertinib in EGFR Mutation-Positive Non-Small Cell Lung Cancer Patients with Poor Performance Status

Takamizawa, S., Okuma, Y., Kato, Y. X., Hakozaki, T., Kitagawa, S., & Zenke, Y. (2021) · Future Oncology · doi:10.2217/fon-2021-0947 · Cited by 8

Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence data

Saito, A., Terai, H., Kim, T. J., Emoto, K., Kawano, R., Nakamura, K., Hayashi, H., Takaoka, H., Ogata, A., Kinoshita, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.7077 · Cited by 7

A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

Minemura, H., Yokouchi, H., Azuma, K., Hirai, K.-I., Sekine, S., Oshima, K., Kanazawa, K., Tanino, Y., Inokoshi, Y., Ishii, T., et al. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1214-9 · Cited by 7

Is the current diagnostic algorithm reliable for selecting cases for EGFR- and KRAS-mutation analysis in lung cancer?

Vincenten, J. P. L., Smit, E. F., Grünberg, K., Postmus, P. E., Snijders, P. J. F., Lissenberg-Witte, B. I., Heideman, D. A. M., & Thunnissen, E. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.04.005 · Cited by 7

First- or Second-line Gefitinib Therapy in Unknown Epidermal Growth Factor Receptor Mutants of Non–Small-Cell Lung Cancer Patients Treated in Taiwan

Lie, C.-H., Chang, H., Chao, T.-Y., Chung, Y., Wang, J.-L., Wang, C., & Lin, M. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.03.006 · Cited by 7

Current status of chemotherapy use and clinical outcome in octogenarians with advanced non-small cell lung cancer

Sim, S. H., Kim, Y. J., Kim, S. H., Keam, B., Kim, T. M., Lee, S., Kim, D., Heo, D. S., & Lee, J. S. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1875-0 · Cited by 7

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Hata, A., Katakami, N., Fujita, S., Nanjo, S., Takeshita, J., Tanaka, K., Kaneda, T., Nishiyama, A., Nishimura, T., Nakagawa, A., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2755-2 · Cited by 7

Association between poor performance status and risk for toxicity during erlotinib monotherapy in Japanese patients with non-small cell lung cancer: Okayama Lung Cancer Study Group experience

Hotta, K., Kiura, K., Takigawa, N., Suzuki, E., Yoshioka, H., Okada, T., Kishino, D., Ueoka, H., Inoue, K., Tabata, M., et al. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.03.008 · Cited by 7

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

Davies, R. S., Smith, C., Edwards, G., Butler, R., Parry, D., & Lester, J. F. (2017) · Lung Cancer International · doi:10.1155/2017/9614938 · Cited by 7

Nasogastric tube‐administered alectinib achieved long‐term survival in a crizotinib‐refractory nonsmall cell lung cancer patient with a poor performance status

Kanai, O., Kim, Y. H., Nakatani, K., Fujita, K., & Mio, T. (2017) · Clinical Case Reports · doi:10.1002/ccr3.973 · Cited by 7

Efficacy of osimertinib in a patient with non‑small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status

Nishii, Y., Hataji, O., Ito, K., Watanabe, F., Kobayashi, T., D’Alessandro‐Gabazza, C. N., Toda, M., Taguchi, O., Yamamoto, N., & Gabazza, E. C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1522 · Cited by 7

Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study

Kashiwabara, K., Fujii, S., Tsumura, S., & Sakamoto, K. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03344-1 · Cited by 7

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer

Takenaka, T., Inamasu, E., Yoshida, T., Toyokawa, G., Nosaki, K., Hirai, F., Yamaguchi, M., Seto, T., Takenoyama, M., & Ichinose, Y. (2015) · Surgery Today · doi:10.1007/s00595-015-1200-9 · Cited by 7

Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts.

Suda, K., Tomizawa, K., Mizuuchi, H., Ito, S., Kitahara, H., Shimamatsu, S., Kohno, M., Yoshida, T., Okamoto, T., Maehara, Y., et al. (2012) · Europe PMC (PubMed Central) · Cited by 7

Clinical outcomes of 1st-line gefitinib for patients with advanced NSCLC harboring EGFR mutations and poor PS

Miura, Y., Minato, K., Fujimoto, S., Sunaga, N., & Yamada, M. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv472.138

First-line gefitinib for poor PS patients with EGFR mutations

Kobayashi, K., Inoue, A., Usui, K., Maemondo, M., Okinaga, S., Mikami, I., Ando, M., Gemma, A., Morita, S. H., & Hagiwara, K. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8070 · Cited by 3

Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.

Okuma, Y., Hosomi, Y., Nagamata, M., Yamada, Y., Sekihara, K., Kato, K., Hishima, T., & Okamura, T. (2013) · PubMed · Cited by 12

Clinical Outcomes After First-Line Egfr-Tki for Patients with Nsclc, Egfr Mutation, and Poor Performance Status

Nagamata, M., Okuma, Y., Sunami, K., Hosomi, Y., & Okamura, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu436.90

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509